| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.09 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.1 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.25 | 0.1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.29 | 0.1 |